Compare MXL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | NUVB |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2009 | N/A |
| Metric | MXL | NUVB |
|---|---|---|
| Price | $22.03 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $19.80 | $11.38 |
| AVG Volume (30 Days) | 930.5K | ★ 3.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $478,596,000.00 | N/A |
| Revenue This Year | $22.10 | $205.55 |
| Revenue Next Year | $10.70 | $58.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.08 | $1.57 |
| 52 Week High | $21.63 | $9.75 |
| Indicator | MXL | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 73.61 | 55.66 |
| Support Level | $15.97 | $4.06 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 0.87 | 0.24 |
| MACD | 0.51 | 0.10 |
| Stochastic Oscillator | 100.00 | 89.27 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.